Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
Sara Lega, Becky L. Phan, Casey J. Rosenthal, et al.
Inflammatory Bowel Diseases (2018) Vol. 25, Iss. 1, pp. 134-141
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, Adam S. Cheifetz, Gil Y. Melmed, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 17, Iss. 9, pp. 1655-1668.e3
Open Access | Times Cited: 274
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Adam S. Cheifetz, María T. Abreu, Waqqas Afif, et al.
The American Journal of Gastroenterology (2021) Vol. 116, Iss. 10, pp. 2014-2025
Open Access | Times Cited: 151
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Konstantinos Papamichael, Waqqas Afif, David Drobne, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 2, pp. 171-185
Open Access | Times Cited: 109
New Therapeutics for Ulcerative Colitis
Robert Hirten, Bruce E. Sands
Annual Review of Medicine (2021) Vol. 72, Iss. 1, pp. 199-213
Closed Access | Times Cited: 104
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Konstantinos Papamichael, Erik H Vogelzang, Jo Lambert, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 8, pp. 837-848
Closed Access | Times Cited: 90
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease
Samuel Fernandes, Sónia Bernardo, Carolina Simões, et al.
Inflammatory Bowel Diseases (2019) Vol. 26, Iss. 2, pp. 263-270
Open Access | Times Cited: 86
Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity
Marla C. Dubinsky, Michelle Mendiolaza, Becky L. Phan, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 9, pp. 1375-1385
Closed Access | Times Cited: 57
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
Thomas Chapman, C Frias Gomes, Édouard Louis, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 5, Iss. 1, pp. 63-79
Open Access | Times Cited: 71
Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response
Miles Sparrow, Konstantinos Papamichael, Mark G. Ward, et al.
Journal of Crohn s and Colitis (2019) Vol. 14, Iss. 4, pp. 542-556
Open Access | Times Cited: 69
TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User’s Guide: An Update
Marianne Vullièmoz, Stephan Brand, Pascal Juillerat, et al.
Digestion (2020) Vol. 101, Iss. Suppl. 1, pp. 16-26
Open Access | Times Cited: 62
Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Laura E. Targownik, Eric I. Benchimol, Çharles N. Bernstein, et al.
Journal of Crohn s and Colitis (2020) Vol. 14, Iss. 10, pp. 1354-1363
Closed Access | Times Cited: 51
Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study
Esteban Fuentes-Valenzuela, Francisco Javier García‐Alonso, Carlos Maroto-Martín, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1586-1593
Closed Access | Times Cited: 20
Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease
Namita Singh, Marla C. Dubinsky
Springer eBooks (2023), pp. 445-456
Closed Access | Times Cited: 16
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study
Emily Stenke, Donya Al‐Hassan, Molly Moclair, et al.
Inflammatory Bowel Diseases (2025)
Closed Access
Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
John L. Lyles, Aditi Mulgund, Laura Bauman, et al.
Inflammatory Bowel Diseases (2020) Vol. 27, Iss. 4, pp. 482-492
Open Access | Times Cited: 45
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
Konstantinos Papamichael, Vipul Jairath, Guangyong Zou, et al.
BMJ Open (2022) Vol. 12, Iss. 4, pp. e057656-e057656
Open Access | Times Cited: 25
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease
Christopher Ma, Robert Battat, Vipul Jairath, et al.
Current Treatment Options in Gastroenterology (2019) Vol. 17, Iss. 1, pp. 127-145
Closed Access | Times Cited: 39
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
David Drobne, Tina Kurent, Saša Golob, et al.
Alimentary Pharmacology & Therapeutics (2019) Vol. 49, Iss. 7, pp. 880-889
Closed Access | Times Cited: 36
Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease
Ruben J. Colman, Ye Xiong, Tomoyuki Mizuno, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 5, pp. 593-603
Open Access | Times Cited: 29
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Early proactive monitoring of DNA-thioguanine in patients with Crohn’s disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers
Ting Yang, Kang Chao, Xia Zhu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 12, pp. 1751-1763
Open Access | Times Cited: 3
How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
Samuele Naviglio, Paolo Giuffrida, Gabriele Stocco, et al.
Expert Review of Gastroenterology & Hepatology (2018) Vol. 12, Iss. 8, pp. 797-810
Closed Access | Times Cited: 34
Page 1 - Next Page

Scroll to top